Aggregator
夹板治疗婴儿髋关节脱位和浅髋关节
Featured review: House modifications for preventing malaria
Installing mosquito screening over house windows and closing the gaps in house eaves can help reduce infection with Plasmodium parasites and the number of people with anaemia in the household, according to an updated Cochrane Review published this week. Householders can implement many of these house modifications themselves, providing a simple malaria prevention tool to complement existing vector control strategies.
The review author team, from the UK, Spain, South Africa, and Malawi, included one randomized controlled trial (RCT) and six cluster-RCTs, and noted an additional six ongoing trials. Trials assessed screening of windows, doors, eaves, ceilings, or any combination of these; this was either alone, or in combination with roof modification or eave tube installation (an insecticidal "lure and kill" device that reduces mosquito entry whilst maintaining some air flow).
The seven included trials, conducted in sub-Saharan Africa, showed that people living in modified houses were less likely to have Plasmodium parasites in their blood, and were less likely to experience moderate or severe anaemia. There was also a large reduction in the number of mosquitoes trapped indoors at night in some of the included trials.
This approach is not a new phenomenon; research from 1901 first demonstrated the effect of simple house screening techniques for protecting families in Italy from mosquito-related illness, and many householders globally continue to screen their homes to protect from nuisance insects. House modifications may provide an important, long-term, sustainable option to reduce malaria.
CIDG Research Associate and lead author Tilly Fox noted, “These results are encouraging, and the reduction in indoor mosquitoes will mean householders will be motivated to screen houses simply to reduce the nuisance factor as well as the health benefits”.
Professor Steve Lindsay from Durham University said, “It is gratifying to see the protective effect of house screening against malaria in different sites. For the future, innovative new solutions are needed to provide better and longer-lasting protection, including tougher screened windows, self-closing doors, and re-designing housing which will help keep the occupants healthy, comfortable, and secure.”
- Read the full review and plain language summary here
- Visit the Cochrane Infectious Diseases Group here
Fox T, Furnival-Adams J, Chaplin M, Napier M, Olanga EA. House modifications for preventing malaria. Cochrane Database of Systematic Reviews 2022, Issue 10. Art. No.: CD013398. DOI: 10.1002/14651858.CD013398.pub4.
Article originally published on Liverpool School of Tropical Medicine website
Friday, October 7, 2022Cochrane seeks Director of Publishing and Technology - UK, remote
Specifications: Full Time (Permanent role)
Salary: £85,000 per annum
Location: UK, homebased and remote-working (attendance at meetings will be expected to pursue development and build relations)
Application Closing Date: Wednesday 19 October 2022, 9am GMT
Cochrane aims to put evidence at the heart of health decision-making globally. We collaborate to produce trusted synthesized evidence, make it accessible to all, and advocate for its use. Cochrane is seeking a Director of Publishing and Technology.
Cochrane is a charity and a global, independent network of health practitioners, researchers, patient advocates and others, responding to the challenge of making vast amounts of research evidence useful for informing decisions about health. They do this by synthesising research findings to produce the best available evidence on what works. Their work has been recognised as the international gold standard for high quality, trusted information.
As a member of the Executive Leadership Team, this role will lead the Publishing and Technology Directorate (comprising Cochrane Library partnership, Informatics and IT Services, product and business development) to drive high performance, organizational growth and financial returns to Cochrane.
Cochrane is seeking an ambitious individual who relishes a challenge, loves collaborative working, delivers results and has experience of successfully delivering strategy. The ideal candidates will possess an understanding and experience of leading the management and development of a portfolio of products and services that are appropriately priced to generate income. You will support Cochrane to navigate a sustainable and realistic route to Open Access publishing, working with the leadership team, expert advisers, the Governing Board and our publisher (Wiley). Finally, you will be enterprising and a strategic thinker with the ability to seek and find creative solutions and foster innovation in your teams.
Cochrane welcomes applications from a wide range of perspectives, experiences, locations and backgrounds; diversity, equity and inclusion are key to their values.
How to apply
To obtain the candidate pack and further information on how to apply please contact:
Abigail Barclay
Search Director
a.barclay@inspiredselection.com
PLEASE NOTE: The recruitment agency will be longlisting applications as soon as they receive them, so please apply early to register your interest.
The Robert Wood Johnson Foundation Awards $1M to Texas Christian University towards the Cochrane US Network
Funding will support the centering of racial health equality in systematic reviews through national consensus building.
The Robert Wood Johnson Foundation (RWJF) is the largest American philanthropic organization focused solely on health and healthcare. The recent grant of $1 Million awarded to members and partners of the Cochrane US Network, including Texas Christian University (TCU), RTI International, Campbell Collaboration, Marymount University, and Georgia College, will support critical research to center racial health equity in systematic reviews through national consensus building.
RWJF defines health equity to means that everyone has a fair and just opportunity to be as healthy as possible, which requires removing obstacles to health such as poverty, discrimination, and their consequences. Systematic reviews—rigorous and comprehensive syntheses and critical appraisal of evidence—is a gold standard research tool to improve dissemination of evidence-based practices that can reduce or eliminate disparities. To date, guidance documents for systematic reviews have not routinely considered health equity when- selecting topics, considering outcomes, conducting critical appraisal, assessing applicability of evidence to specific populations or settings, nor when communicating findings to key stakeholders and communities.
Cochrane Senior Officer Us Network, Tiffany Duque, states “by establishing standards to improve the methods, conduct, and reporting of systematic reviews specific to racial health equity, Cochrane can help reduce racial health disparities in the US. With this Robert Wood Johnson funding we will assess the gaps in primary and secondary research to help improve and guide future evidence synthesis toward improved racial health equity.”
This award is the largest to date for the Cochrane US Network, which was established in 2019. Catherine Spencer, Cochrane CEO states, “Racial health equality is a priority topic for Cochrane, the US, and globally. We encourage Cochrane reviews to include explicit descriptions of methods, effects of the interventions, and ability to reduce inequalities in health and to promote their applicability to all population groups. Cochrane is proud to lend its leadership and expertise to this project.”
This prestigious collaboration of investigators and institutions will undertake a comprehensive and ambitious effort to listen to stakeholders and communities, perform landscape analyses of existing resources, and prioritize next steps as the first phase to centering racial health equity in systematic reviews. Principal Investigators include awardee Dr. Dru Riddle (TCU), Dr. Meera Viswanathan (RTI), Dr. Vivian Welch (Campbell), Dr. Patricia Heyn (Marymount), Dr. Damian Francis (Georgia College), and Tiffany Duque (Cochrane).
Announcing the 2023 Cochrane Colloquium in London, UK
Cochrane London 2023: Forward together for trusted evidence
4-6 September 2023
Central London, UK
Cochrane is an international non-profit network that provides evidence-based scientific knowledge to improve healthcare for all people worldwide. Cochrane Reviews summarise all available research on a specific health question. They are up-to-date, follow a rigorous scientific methodology, and are free from commercial conflicts of interest. Health professionals, patients, and policy makers trust Cochrane Reviews for their healthcare decision-making. Cochrane works with researchers, health professionals, patients, policy makers, and media representatives from around the world to make Cochrane Reviews relevant and usable.
Cochrane holds an annual conference, known as a Colloquium, that brings together Cochrane researchers, clinical professionals, early career professionals, patients and carers, policymakers, and anyone interested in evidence synthesis and evidence-based healthcare. The events are a mix of keynote speakers, training opportunities, workshops, presentations, and a lively social and networking atmosphere. They are an exciting opportunity for a community of evidence synthesis enthusiasts to share, learn, and connect.
Cochrane was founded 30 years ago in Oxford and to mark this anniversary the colloquium will be held in the United Kingdom. It will take place at the QEII Centre in Westminster, Central London, hosted by Cochrane UK. The main programme will run from the 4th to the 6th of September, with satellite events and meetings on the 3rd September 2023.
This will be the first time the Cochrane community has come together since 2018 and in recognition of this, it is being designed to celebrate the diverse, global and cohesive nature of the collaboration that is Cochrane. As in previous years there will be stipends to make it possible for students, early career professionals and those from low-and middle-income countries to attend. The Colloquium theme is forward together for trusted evidence.
Martin Burton, Director of Cochrane UK, said: “After 30 years of producing and advocating for the use of high-quality evidence, Cochrane can look back on many significant achievements. Now we need to look forward together.”
Catherine Spencer, Cochrane CEO said, “The 2023 Cochrane Colloquium is an event for everyone with an interest in the use of evidence in healthcare decision making. We welcome those engaged in evidence production, co-production, dissemination, implementation and policy making, as well as those making individual healthcare decisions to join us for this exciting event.”
Registration will open in early 2023. Scientific programme will be announced in the coming months.
- Find out more at the Colloquium website
- #CochraneLondon
- Press contact: Katie Abbotts, Cochrane UK
哪种激素疗法对卵巢早衰的女性更有效?
Editorial: Achieving sustainable healthcare through deprescribing
A new Cochrane Library Editorial has been published about the overtreatment with multiple medications and potentially inappropriate medications use in frail, older adults, and people with multimorbidity.
The editorial introduces the Cochrane Library Special Collection on deprescribing which provides a summary of Cochrane Reviews on the topic. This collection of reviews highlight that deprescribing is likely feasible and safe and can lead to benefits in prescribing and clinical outcomes. However, they also highlight significant gaps in the literature and methodological challenges to both conducting deprescribing studies and systematic reviews of deprescribing. The editorial calls on the deprescribing research field to focus on universally accepted standards, definitions, and checklists and work collaboratively with Cochrane Sustainable Healthcare.
Wednesday, October 5, 2022Featured review: Survivor, family and professional experiences of interventions for sexual abuse and violence
成人大腿骨下部骨折的治疗
Mental health support in the community for refugee children and adolescents in high-income countries
上肢锻炼方案对肾衰竭患者的动静脉瘘成熟有效吗?
电磁导航或内窥镜引导方法:哪种更适合将饲管置入小肠?
Recording: 2022 Cochrane Lecture with Jimmy Volmink
In November 2022 Jimmy Volmink, the 'father of evidence-based medicine in Africa' and dedicated Cochrane member was the speaker for the 2022 Cochrane Lecture.
Cochrane Lectures provide a forum for influential thinkers to deliver thought-provoking talks on the key challenges for the future Evidence-Based Medicine.
Cochrane’s vision is for a world in which “decisions about health and care are informed by high-quality evidence.” As a trusted source of evidence, the organisation is making a substantial contribution to the realisation of this ideal. Yet, more can be done to extend Cochrane’s global reach, and enhance its relevance and impact worldwide. In this year’s Cochrane Lecture, Professor James "Jimmy" Volmink called for the adoption of global health equity as a strategic priority for Cochrane, and explored ways this can be actioned through steps such as prioritising review topics, enabling participation and promoting diversity and inclusion.
Professor Volmink, the founding Director of the South African Cochrane Centre has a lifelong unwavering commitment to keep on 'banging the drum about inequality' to affect real change. Jimmy reflects on his personal and professional journey in this 'Recommended Dose' podcast.
Thursday, December 1, 2022National Eye Institute Awards $5 Million for Cochrane Eyes and Vision US Project
The award supports critical research to help identify treatments to improve the lives of people suffering from debilitating eye diseases.
The National Eye Institute (NEI) has awarded a $5 million grant to Tianjing Li, PhD, associate professor of ophthalmology at the University of Colorado School of Medicine, in a continuation of the NEI’s support of the Cochrane Eyes and Vision US Satellite (CEV US Satellite) at the Sue Anschutz-Rodgers Eye Center.
The award is one of the largest grants the CU Department of Ophthalmology has received from the NEI and ensures the project will remain on the CU Anschutz Medical Campus for the next five years.
“We are very grateful for NEI’s continued support in the research we are doing,” says Li. “It will help us grow new partnerships, produce trustworthy evidence, and ultimately improve the vision care our patients receive.”
The Cochrane Eyes and Vision (CEV) US Satellite is a team of US-based researchers and practitioners who review medical literature for content covering interventions to prevent or treat eye conditions and visual impairments and to help people adjust to visual impairment or blindness. CEV is a member review group of the Cochrane US Network, which formed in 2019. Cochrane Senior Officer Tiffany Duque states "this grant is an exciting achievement for the US Network, and we thank Dr. Li for her continued efforts and dedication not only to CEV but also to the US Network. We look forward to the high-quality evidence that will result from this grant, and to engaging other US Cochrane Centers in ensuring national dissemination of this important work."
“Cochrane systematic reviews are published in the Cochrane Library, which contains high-quality, independent evidence to inform health care decision-making,” says Li, principal investigator for the CEV US Satellite. “These reviews are valuable sources of information for those receiving and providing care, as well as for policymakers and researchers. Our reviews have been highly cited by national and international practice guidelines.”
Although the reviews are written for health care professionals, each review can also help to assist patients and the public in making informed health care decisions. Topics for reviews are identified based on gaps in the literature, importance of the topics to influence practice, and from interest and suggestions of patients and experts in the field. Once a review topic has been identified, Li’s team works with eye doctors to produce the review, which is then peer reviewed and ultimately published in the Cochrane Library.
“We are very proud of the program Dr. Tianjing Li has built here in the Sue Anschutz-Rodgers Eye Center,” says Naresh Mandava, MD, chair of the CU Department of Ophthalmology and Sue Anschutz-Rodgers Endowed Chair in Retinal Diseases. “Evidence-based medicine is critical to our understanding of disease and identifying effective therapies that will ultimately improve the lives of people suffering from debilitating eye diseases. The Cochrane project centered here at CU leads the way in this endeavor and we appreciate the National Eye Institute’s continued support of this important work.”
The project’s mission to promote informed health care decision-making and research is critical amid the current climate of increasing health care disparities and growth of health care misinformation from online sources.
“Vision health care should be based on science,” Li says. “In this era of data deluge, evidence-informed practice is needed more than ever.”
Since 2002, the CEV US Satellite has published more than 120 systematic reviews and more than 90 methodological papers and book chapters. The project has also trained more than 120,000 individuals in methods for systematic reviews and has informed hundreds of clinical practice guidelines in the United States and internationally.
诊断为自闭症谱系障碍的学龄前儿童在一年或多年后保留诊断的比例如何?
非小细胞肺癌患者肺部手术前的运动训练
体外光分离置换术用于儿童和青少年造血干细胞移植后急性移植物抗宿主病
右雷佐生可以预防或减少接受蒽环类药物治疗的成人和儿童的心脏损伤吗?
Cochrane seeks Publishing Systems Support Specialist
Location: Flexible location (remote working) – contract type dependent on location.
Specifications: Permanent employment contract if successful applicant based in UK, Germany or Denmark. Consultancy contract in other locations.
Salary: £36,000 per annum
Application Closing Date: 18 October 2022
Cochrane is a charity and a global, independent network of health practitioners, researchers, patient advocates and others, responding to the challenge of making vast amounts of research evidence useful for informing decisions about health. They do this by synthesising research findings to produce the best available evidence on what works. Their work has been recognised as the international gold standard for high quality, trusted information.
The core purpose of this role is to ensure that Cochrane systems are presented coherently to our users, are well-documented, tested, fit for purpose and that the user voice is heard in system development decision-making.
You will:
- provide second-line expert support on software used by Cochrane authors and staff to write and edit Cochrane Reviews:
- Editorial Manager (third-party software from Aries Systems)
- project management features in RevMan Web (in-house review development software)
- act as System Administrator for these systems, making configuration changes to optimise user experience
- update supporting documentation and run demos to educate users on system configurations
- input into projects and programmes of work which impact on Cochrane authors and staff
- represent the user voice in system development, based on feedback received from support cases and training
- use your knowledge to influence development priorities and project decisions that have an impact on system users
Cochrane welcomes applications from a wide range of perspectives, experiences, locations and backgrounds; diversity, equity and inclusion are key to their values.
How to apply
- For further information on the role and how to apply, please click here.
- The deadline to receive your application is by 18 October 2022.
- The supporting statement should indicate why you are applying for
- Read our Recruitment Privacy Statement